AbbVie Ends Rova-T Program as 3rd Lung Cancer Study Fails - Zacks.com
AbbVie Ends Rova-T Program as 3rd Lung Cancer Study Fails Zacks.com
IDMC recommends termination of AbbVie's (ABBV) late-stage study on its small cell lung cancer candidate, Rova-T. AbbVie discontinues development.
Comments
Post a Comment